Oral Administration of the NMDA Receptor Antagonist S-Ketamine as Add-On Therapy of Depression: A Case Series

We intended to assess safety, response to treatment and time to response of 1.25 mg/kg oral S-ketamine as add-on to standard antidepressants in four depressed patients. Two patients with melancholic depression responded early and stayed in remission, while two patients with distinct somatic symptoms, chronicity or atypical features did not respond. The limited number of patients does not allow conclusions about efficacy. Oral S-ketamine was well tolerated and could merit being studied in randomised controlled trials due to its higher practicability compared to (S-)ketamine infusion therapy. Clinical subtyping should be considered.

References

• 1 Bausewein C, Remi C, Twycross RG. et al . (Eds.)  Arzneimitteltherapie in der Palliativmedizin. (German edition of Palliative Care Formulary, by Twycross RG, Wilcock A, Charlesworth S, et al.) 
• 2 Berman RM, Cappiello A, Anand A. et al . Antidepressant effects of ketamine in depressed patients.  Biol Psychiatry. 2000;  47 351-354
• 3 Correll GE, Futter GE. Two case studies of patients with major depressive disorder given low-dose (subanesthetic) ketamine infusions.  Pain Med. 2006;  7 92-95
• 4 Enarson MC, Hays H, Woodroffe MA. Clinical experience with oral ketamine.  J Pain Symptom Manage. 1999;  17 384-386
• 5 Ghai B, Grandhe RP, Kumar A. et al . Comparative evaluation of midazolam and ketamine with midazolam alone as oral premedication.  Paediatr Anaesth. 2005;  15 554-559
• 6 Goforth HW, Holsinger T. Rapid relief of severe major depressive disorder by use of preoperative ketamine and electroconvulsive therapy.  J ECT. 2007;  23 23-25
• 7 Hocking G, Cousins MJ. Ketamine in chronic pain management: an evidence-based review.  Anaesth Analg. 2003;  97 1730-1739
• 8 Liebrenz M, Stohler R, Borgeat A. Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression.  World J Biol Psychiatry. 2007;  10 1-4
• 9 Ostroff R, Gonzales M, Sanacora G. Antidepressant effect of ketamine during ECT.  Am J Psychiatry. 2005;  162 1385-1386
• 10 Paul R, Schaaff N, Padberg F. et al . Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: Report of two cases.  World J Biol Psychiatry. 2007;  1-4
• 11 Phelps LE, Brutsche N, Moral JR. et al . Family history of alcohol dependence and initial antidepressant response to an N-methyl-d-aspartate antagonist.  Biol Psychiatry. 2009;  65 181-184
• 12 Sinner B, Graf BM. Ketamine.  Handb Exp Pharm. 2008;  182 313-333
• 13 Thompson C. Onset of action of antidepressants: results of different analyses.  Hum Psychopharmacol. 2002;  17 ((Suppl 1)) S27 S32 [Review] 
• 14 Trivedi MH, Rush AJ, Wisniewski SR. et al . STAR*D Study Team   Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.  Am J Psychiatry. 2006;  163 28-40
• 15 Zarate  Jr CA, Singh JB, Carlson PJ. et al . A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression.  Arch Gen Psychiatry. 2006;  63 856-864

Correspondence